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nadectomy, the patient developed recurrent painful cystic 
swellings of the remaining gonad. Because of the wish to 
preserve hormonal activity as well as future fertility, the pa-
tient underwent surgical resection of a cystic gonadal area. 
The removed tissue showed ovulation-related features in 
addition to both testicular and ovarian tissue, diagnosed as 
an ovotestis. Testosterone therapy was initiated to suppress 
the persistently elevated gonadotropins and thereby sup-
press ovarian activity. During treatment, the recurrent pain 
complaints and cystic swellings ceased, although gonado-
tropin levels were not fully suppressed. Based on these ob-
servations, the importance of a detailed genetic and patho-
logical diagnosis and the clinical dilemmas including the 
pros and cons of personalized treatment with gonadal pre-
servative surgery are discussed.  © 2017 The Author(s)
Published by S. Karger AG, Basel 
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 Abstract 
 We report on an adult male initially presenting with gyneco-
mastia and a painless scrotal mass without additional genital 
anomalies. Hyperpigmentation of the skin following the 
Blaschko’s lines was identified. He underwent gonadectomy 
because of suspected cancer. Histological analyses revealed 
an ovotestis with ovulatory activity confirmed by immuno-
histochemistry with multiple markers. Karyotyping of cul-
tured peripheral blood lymphocytes and a buccal smear re-
vealed a 46,XX/46,XY chimeric constitution with different 
percentages. Multiple molecular analyses as well as blood 
typing implied a tetragametic origin. After the unilateral go-
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 The genetic basis of specific types of disorders of sex de-
velopment (DSD) remains partly unexplained, which can 
be due to various reasons, including absence of informa-
tive data as well as the actual inability to interpret the data 
if present. This also applies to possible chimerism, de-
fined as the presence of 2 separate genetic cell lines with-
in a single individual. It can be limited to a single tissue 
or affect multiple or even all tissues [Lee et al., 2014; Xia 
et al., 2014]. A number of clinical interventions can cause 
chimerism, including transplantation and prenatal trans-
fusion. Alternatively, it can be related to a disturbed fer-
tilization and may have a dispermic, tetragametic, or par-
thogenetic origin. The actual prevalence of these alterna-
tive mechanisms is unknown, as it is expected that many 
of the affected individuals are in fact healthy and are only 
incidentally identified for example by blood group or pa-
ternity/maternity testing or other clinical investigations 
related to health issues [Zhu et al., 2014]. However, detec-
tion of chimerism has become feasible with the applica-
tion of targeted as well as genome-wide single nucleotide 
polymorphism (SNP) analyses, as recently demonstrated 
[Conlin et al., 2010].
 Identification of the presence of chimerism can be 
relevant in the context of elucidation of the genetic 
mechanism underlying various forms of DSD, including 
ovotesticular-DSD (OT-DSD). This is a rare form of 
DSD, diagnosed on defined histological characteristics 
of gonadal tissue. Specifically, both testicular and ovar-
ian tissue must be present in a single patient, although 
not restricted to a single gonad. Importantly, the testicu-
lar tissue can be devoid of germ cells, while the presence 
of (female) germ cells (oogonia/oocytes) is a prerequisite 
for the classification of the ovarian component. These 
definitions must be followed strictly to prevent overdi-
agnosis of this variant of DSD with clinical implications. 
It is not easy to identify patients with OT-DSD based on 
the genital phenotype, because this may vary from am-
biguous to atypical to normal genitalia. Also at the level 
of chromosomal and molecular constitution, patients 
with OT-DSD can be highly heterogeneous. About 60% 
have a 46,XX karyotype, which was recently suggested to 
be due to mutations in  NR5A1 [Baetens et al., 2016; 
Bashamboo et al., 2016; Igarashi et al., 2017]. A cytoge-
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 Fig. 1. Histology and immunohistochemistry of the gonad after 
gonadectomy demonstrating an ovotestis.  A Representative hema-
toxylin and eosin (HE) staining showing an overview of the whole 
gonad. Testicular tissue is present in the upper right part, while the 
rest of the gonad consists of ovarian tissue including a follicular 
cyst.  B HE-stained section showing the presence of a primordial 
follicle in the surrounding ovarian stroma. Positive DDX4 (VASA) 
staining of the primordial follicle ( Inset ).  C Representative HE 
staining of the testicular tissue showing the presence of seminifer-
ous tubules with spermatogenesis (right side) next to the seminif-
erous tubules with Sertoli-cell-only (left side).  D DDX4 (VASA) 
positive spermatogonial cells present in a subset of the seminifer-
ous tubules (right side, brown).  E Positive staining of spermatogo-
nia with TSPY (red).  F Representative part of the testicular tissue 
showing absence of OCT3/4 (POU5F1)-positive staining. Positive 
control (brown,  inset ).  G The granulosa cells in the ovarian stroma 
and surrounding the primordial follicle show expression of FOXL2 
(brown).  H Positive SOX9 staining (brown) of the Sertoli cells pres-
ent in the seminiferous tubules. Note the presence of spermatogen-
esis in the tubules on the right side next to Sertoli-cell-only tubules 
(left side).  I ,  J Representative FISH with Y centromere (red) and X 
centromere (green) probes. Note the presence of Y centromeres in 
cells surrounding the primordial follicle next to cells showing 2 X 
centromere signals; within the seminiferous tubules most cells 
show an XY constitution.  A ×5,  B–H ×400. 
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netic explanation of OT-DSD is identified in about 30% 
of the patients [Ledig et al., 2012]. For many decades it 
has been realized that a 46,XX/46,XY chromosomal con-
stitution can be an isolated sex chromosome abnormal-
ity related to OT-DSD, in which case the autosomes 
show a similar molecular constitution in both cell lines 
[De Marchi et al., 1976; Niu et al., 2002; Alonso et al., 
2007]. Alternatively, it can be caused by chimerism, 
characterized by a different molecular constitution of 
the autosomes present in the cell lines because of the 
origin from (at least) 2 different gametes [Zuffardi et al., 
1987; Xia et al., 2014].
 Here, we report on a male patient with tetragametic 
chimeric OT-DSD, diagnosed by various approaches, in-
cluding blood typing as well as genome-wide and targeted 
SNP analyses. His condition can only be explained by the 
mixtures of 2 independently fertilized oocytes, one with 
an X- and one with a Y-containing sperm, explaining the 
2 diploid cell line constitution combined with the pres-
ence of up to 4 individual alleles. The patient described 
underwent a complete unilateral gonadectomy because of 
suspected cancer and subsequent partial contralateral go-
nadectomy because of remaining ovarian activity. The 
testicular part was left in situ to preserve testicular tissue 
for hormonal activity as well as putative future fertility. 
Hormonal treatment was applied to subsequently sup-
press the remaining ovarian activity, resulting in pain re-
lief. The relevance of the genetic and pathological gonad-
al diagnosis will be discussed in the context of optimal 
clinical management in this single patient.
 Case Report 
 A 19 year-old male, born from a Caucasian father and an Asian 
mother, presented to a local hospital with a painless right scrotal 
mass. Unilateral gonadectomy was performed because of suspi-
cion of testicular cancer. Histological investigation at a peripheral 
pathology institute resulted in the diagnosis of a typical ovotestis 
( Fig. 1 A–C). The patient was referred to the Erasmus MC DSD 
expert team for further treatment. The gonadal histology was con-
firmed by the referral pathologist, and additional confirmative 
immunohistochemical stainings, including DDX4, TSPY and 
OCT3/4 (POU5F1), SOX9 and FOXL2, were performed ( Fig. 1 ). 
His medical history was unremarkable, except for an asymmetrical 
gynecomastia since the onset of puberty at the age of 14 years. He 
had no history of cryptorchidism. Physical examination showed a 
slender male, normal virilized phenotype with persisting asym-
metric gynecomastia, Tanner stage B4 on the right side and B2 on 
the left side, normal male external genitalia, a left scrotal gonad 
with a volume of 12–15 mL with a normal texture on ultrasound, 
and an empty right hemi-scrotum after the unilateral gonadecto-
my. Several striking irregular pigmentations on the right shoulder 
and upper arm with a distribution reminiscent of Blaschko’s lines 
were identified ( Fig. 2 ).
 Endocrinological and Imaging-Based Evaluation 
 Laboratory investigations ( Table 1 ) showed elevated gonado-
tropins and a testosterone level at the high end of the reference 
range (29 nmol/L, reference range 10–30 nmol/L). Estradiol and 
progesterone were within the male reference range, whereas pro-
lactin was elevated (1.64 U/L, male reference range 0–0.36 U/L). 
Six weeks after the initial presentation, the patient developed a 
cystic mass in the upper part of the remaining gonad. MRI of the 
pelvic region identified an 18 mm cyst in the gonad close to the 
epididymis. In addition, a small prostate, a small utriculus, a nor-
mal aspect of the left seminal vesicle, an underdeveloped right 
seminal vesicle, and possible absence of the vasa deferentia were 
identified. In addition, an uretero pelvic junction stenosis of the 
right kidney was found, but no signs of malignancy. In the follow-
ing year, gonadotropin levels fluctuated. Maximum LH was 
21.8 U/L which coincided with the lowest FSH level (12 U/L) and 
highest estradiol level of 477 pmol/L. At this time, gynecomastia 
progressed to Tanner stage B3 on the left side. The cystic upper 
part of the remaining gonad, which measured 1.2 × 1 × 0.5 cm in 
size, was removed (histological findings are reported below). The 
aim of this partial surgical intervention was the removal of the 
ovarian tissue and resulted in regression of breast tissue on the left 
side. However, 6 months later, the patient had complaints again of 
intermittent pain/discomfort caused by a palpable gonadal cyst, 
likely an ovarian follicle. Laboratory investigations showed that 
estradiol and prolactin levels remained elevated. The patient did 
not decide for gonadectomy because of the resulting loss of hor-
monal function and fertility. In addition, he declined the opportu-
nity to investigate his fertility by semen analysis and possibly cryo-
preservation or testicular sperm extraction (TESE) at that point in 
life. Therefore, treatment with testosterone was initiated, despite 
normal testosterone levels, to suppress LH and thereby suppress 
ovarian activity. During treatment with 50 mg/day transdermal 
testosterone gel, he no longer experienced gonadal pain, despite 
LH and estradiol initially remaining elevated, although levels 
seemed to decline after several months.
 Fig. 2. Representative images of the pigmented areas on the skin 
known as Blaschko’s lines. 
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 Materials and Methods 
 Blood Typing by Monoclonal Antibodies as well as by DNA 
Analysis 
 The ABO blood group typing was done serologically with man-
ually standard gel cards (DiaMed AG, Cressier, Switzerland). Fur-
thermore, an ID-card was used for complete profiling of the Rh-
phenotype, including K-typing. In addition, ABO genotyping was 
performed by sequencing. Furthermore, blood group antigen typ-
ing was performed by real-time quantitative PCR-based allelic dis-
crimination assays for RHCE, RHD, FY, JK, and K by the depart-
ment of immunohematology, Sanquin Diagnostic Services, Am-
sterdam, The Netherlands, using standardized procedures.
 Immunohistological Analyses of Gonadal Tissue 
 Immunohistochemical staining was performed on formalin-
fixed paraffin-embedded gonadal samples of 4 μm thickness. Brief-
ly, after deparaffinization and 5 min incubation in 3% H 2 O 2 
for inactivating endogenous peroxidase activity, antigen retrieval 
was carried out by heating to 120   °   C under pressure up to 0.9 bar 
in 0.01  M TRIS/0.001  M EGTA (pH 9.0) buffer. After blocking en-
dogenous biotin using the Avidin/Biotin Blocking Kit (SP-2001; 
Vector Laboratories), sections were incubated either overnight at 
4   °   C (TSPY) or for 2 h at room temperature (OCT3/4, DDX4, 
SOX9, and FOXL2) and detected using the appropriate biotinyl-
ated secondary antibodies and visualized using the avidin-biotin 
detection and substrate kits (Vector Laboratories). The antibodies 
directed against OCT3/4, TSPY, DDX4 (VASA), SOX9, and 
FOXL2 have been described before [Zeeman et al., 2002; Honeck-
er et al., 2004; Hersmus et al., 2008; Lau et al., 2009].
 Genetic Investigations 
 Standard karyotyping on cultured lymphocytes was performed, 
as well as FISH using centromeric probes for the X (CEPX) and the 
Y chromosome (CEPY) on a buccal smear and on both the ovarian 
and testicular tissue from the removed gonadectomy specimen. 
FISH on tissue slides was performed as follows: slides of 5 μm 
thickness were deparaffinized and heated under pressure of up to 
0.9 bar in appropriate buffer (0.001  M TRIS/EGTA, pH 9). Slides 
were digested using 0.01% pepsin (Sigma Aldrich) in 0.02  M HCl 
at 37  °  C, with an optimal digestion time of 1 min. Slides were rinsed 
and dehydrated, and the probes dissolved in hybridization mixture 
were applied. Probes for centromere X (pBamX5) and centromere 
Y (DYZ3) were used, labeled with digoxigenin-11-dUTP and bio-
tin-16-dUTP (Roche Diagnostics) using a nick-translation kit 
(Gibco BRL). After denaturizing (80  °  C for 10 min), hybridization 
overnight (37  °  C), and washing steps, probes were visualized using 
Cy3-conjugated avidin (1: 100, Jackson ImmunoResearch) and 
Sheep-anti-dig FITC (1: 50, Roche Diagnostics) and analyzed using 
a fluorescent microscope (Leica Microsystems).
 DNA profiling was performed using various approaches. The 
targeted approach, consisting of a set of 15 highly polymorphic 
markers, distributed over 13 autosomes, and 1 sex chromosomal 
marker that differentiates between X and Y chromosomes, was 
performed to establish the number of different parental alleles on 
isolated DNA of peripheral blood lymphocytes (AmpFlSTR ® 
Identifiler ® PCR Amplification Kit, ThermoFisher Scientific). A 
multiplex PCR assay for short tandem repeat (STR) loci was 
applied including the following markers: TPOX (2p25.1pter), 
D2S1338 (2q35), D3S1358 (3p21.31), FGA (4q31.3), D5S818 
(5q23.2), CSF1P0 (5q33.3), D7S820 (7q21.11), D8S1179 (8q24.13), 
TH01(11p15.5), vWA (12p12-pter), D13S317 (13q31.1), D16S539 
(16q24.1), D18S51 (18q21.33), D19S433 (19q12), D21S11(21q21.1), 
and Amelogenin (Xp22.2p22.3 and Yp11.2). Samples were run on 
an ABI 3100 (ThermoFisher Scientific) and were analyzed using 
Genemarker software (SoftGenetics). The genome-wide analysis 
was performed using the Infinium CytoSNP-HC850v1.1 Bead-
Chip (HC850) array according to the Infinium SNP protocol with 
an input of 200 ng DNA. Analysis was performed with GenomeStu-
dio v2011.1 (Illumina) and NexusCopyNumber v8 (BioDiscov-
ery). BioDiscovery’s SNP-Rank Segmentation Algorithm, an ex-
tension of the Rank Segmentation algorithm, was used to make 
Table 1.  Summary of the endocrine investigations
 Time points, weeks
  0 5 32 45a 62 67 73b 100 126
Estradiol, pmol/L 71 161 477H 200H 108 192H 175H 151H 88
TSH, mU/L 1.60
Free T4, pmol/L 13.7 15.5
LH, U/L 11.9H 20.7H 21.7H 6.7 13.4H 18.2H 16.1H 21.8H 10.0H
FSH, U/L 32.7H 14.7H 12.0H 18.4H 31.5H 30.0H 22.2H 29.5H 26.6H
AMH, μg/L 5.3 5.8 5.6 4.9 5.5
Inhibin B, ng/L 32L 25L 18L <10L 22L
Prolactin, U/L 1.64H 1.7H 1.4H 4.1H 1.06H 1.45H 1.17H 1.13H 1.0H
Progesterone, nmol/L 1.4 1.5 1.5 1.3 1.2 1.0
Testosterone, nmol/L 29.14 19.7 18.9 18.4 23.05 24.73 13.75 29.32 26.95
SHBG, nmol/L 73.9H  52.7 64.6
 The time points of the analyses are indicated in weeks after the initial visit to the DSD team (i.e., first measurements were done after 
unilateral gonadectomy). H, above reference range; L , below reference range; a Partial gonadectomy of the remaining gonad. b Start of 
testosterone treatment. 
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copy number as well as loss of heterozygosity (LOH) calls. SNP-
Rank Segmentation takes into account both the log-R as well as the 
B-allele frequency value at each probe location to create a segment. 
The significance threshold for segmentation was set at 5 × 10 –8 , 
also requiring a minimum of 6 probes per segment and a maxi-
mum probe spacing of 1,000 kb between adjacent probes before 
breaking a segment. The log ratio thresholds for single copy gain 
and single copy loss were set at 0.18 and 0.16, respectively. The 
homozygous frequency threshold was set to 0.85, the homozygous 
value threshold was set to 0.8, the heterozygous imbalance thresh-
old was set to 0.4, and the minimum LOH length was set at 1,000 
kb. Moreover, a targeted amplicon primer set was applied, con-
taining 2 constitutions, including 197 (experiment 1) and 330 re-
gions (experiment 2) across the genome of which many were in-
formative based on frequent heterozygous markers designed with 
Ion AmpliSeq TM Designer. Library preparations were performed 
with the AmpliSeq Library Kit 2.0–384 LV. Template preparation 
and sequencing were done with the Ion PGM Hi-Q Chef Kit on an 
Ion 318v2 chip. Sequence information was analyzed with Variant 
Caller v4.4.2.1 (ThermoFisher Scientific), and variants were anno-
tated in a local Galaxy pipeline using ANNOVAR (human genome 
build 37). All heterozygous positions (5–95%) were visually in-
spected [proper alignments, no repeats, no homopolymeric 
stretches, and sufficient reads (>50)]. The average coverage was 
approximately 800 reads for both experiments. Lesser allele fre-
quencies (LAF) were determined for both experiments and data 
were averaged.
 Results 
 Blood Typing 
 Blood grouping showed a double population of O and 
AB erythrocytes ( Fig. 3 ) without a history of blood trans-
fusion. The presence of both A and B antigens was con-
cordant with the absence of anti-A and anti-B antibodies. 
DNA genotyping supported the serological findings. The 
main blood group was O, K negative and K (a) positive, 
while 15% of the erythrocytes expressed both blood 
groups A and B and were positive for K antigen and neg-
ative for K (a) antigen. This indicted the presence of 4 al-
leles, in line with a tetragametic chimerism of which the 
O cell line represented 85% and the AB cell line 15%.
 Gonadal Histology 
 As indicated, histological examination of the right go-
nad obtained after complete gonadectomy showed an 
ovotestis, characterized by a follicular cyst present in an 
ovarian stromal context as well as testicular tissue com-
posed of seminiferous tubules with Sertoli-cell-only and 
tubules with spermatogenesis (representative images of 
hematoxylin and eosin stained slides and immunohisto-
chemical evaluation are shown in  Figure 1 A–H). Immu-
nohistochemical staining for DDX4 showed the presence 
of germ cells at different stages of maturation, supported 
by the positive staining for TSPY. The absence of staining 
for OCT3/4, specific for embryonic stem and germ cells, 
is in line with the morphological interpretation of the ab-
sence of the pre-malignant lesion of germ cell cancers, 
known as germ cell neoplasia in situ (GCNIS) [Berney et 
al., 2016]. In addition, SOX9 stained the Sertoli cells in the 
testicular area of the gonad and FOXL2 the granulosa 
cells in the ovarian part. Similar observations were made 
on the partial surgical specimen of the contralateral go-
nad. In brief, it contained gonadal tissue including semi-
niferous tubules without germ cells (i.e., Sertoli-cell-on-
ly), as well as multiple, although limited, numbers of pri-
mordial follicles. In addition, a regressive structure, likely 
related to a regressive follicle, was identified similar to the 
gonadectomy specimen ( Fig. 1 ).
 Genetic Investigations 
 The cultured leucocyte analysis demonstrated a 46,XX 
karyotype in 23 cells (77%) and a 46,XY karyotype in 7 
cells (23%), indicating a mosaic chromosomal constitu-
tion, with a XX predominance. FISH with centromeric X 
and Y probes on a buccal smear confirmed this observa-
tion, with the following distribution: CEPX×2 in 16/50 
(32%) and CEPX,CEPY×1 in 34/50 (68%) cells, showing 
an XY predominance, in contrast to the investigated leu-
kocytes. FISH with the CEPX and CEPY probes on go-
nadal tissue showed predominantly XX cells in the ovar-
ian tissue and XY in the testicular part; however, both 
tissues contained both sex chromosomal patterns ( Fig. 1 I, 
J). The results are summarized in  Table 2 . Based on the 
 Fig. 3. ID-card (DiaMed, Cressier, Switzerland) for blood groups 
ABO and rhesus D with mononclonal antibodies, showing a mixed 
field agglutination pattern indicating the presence of O group cells 
and the simultaneous presence of erythrocyte populations with a 
weak expression of A and B antigens. Anti-A1 and anti-B antibod-
ies were absent. No mixed field was present for rhesus D. 
 van Bever   et al.
 
Sex Dev 2018;12:145–154
DOI: 10.1159/000479946
150
recurrent XX/XY karyotype, further investigations were 
initiated using both a targeted as well as genome-wide 
SNP-based approach. For the targeted analyses, DNA 
from the patient was compared with DNA of both parents 
using a set of highly polymorphic markers. Six markers 
were found to be informative (TPOX, D2S1338, D3S1358, 
D5S818, D7S820, D18S51). The patterns of the markers 
TPOX, D2S1338, and D3S1358 were informative for the 
presence of an additional paternal allele, whereas the pat-
terns of the markers D5S818 and D7S820 demonstrated 
the presence of an additional maternal allele. The sex 
chromosomal marker Amelogenin showed a more in-
tense X chromosomal specific allele in the patient, com-
pared to the X chromosomal allele in his father (see  Ta-
ble 2 for summary). Marker D18S51 was indicative for the 
presence of 4 different alleles, 2 of paternal and 2 of ma-
ternal origin ( Fig. 4 ). In the DNA of the patient 2 major 
alleles are observed, 1 paternal and 1 maternal. The left 
minor paternal allele in the patient overlaps with a spe-
cific peak preceding the major paternal allele, but its in-
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Test Result
Karyotyping on leucocytes 46,XX[23]/46,XY[7]
FISH on buccal smear CEPX×2[16/50]/CEPX,CEPY×1[34/50]
FISH on ovarian and testicular part of 
gonad, respectively
CEPX×2/CEPX,CEPY×1
Marker D18S51 4 alleles, 2 paternal and 2 maternal
Markers TPOX, D2S1338, D3S1358 extra paternal allele
Markers D5S818, D7S820 extra maternal allele
Marker amelogenin higher signal
ABO blood grouping and phenotyping O K– Jk(a)+/ AB K+ Jk(a)–
SNP array and targeted sequencing aberrant distribution of B allele
Table 2.  Summary of the molecular 
analyses performed
 Fig. 4. Representative example of the pat-
tern of the marker D18S51 in peripheral 
blood DNA of the father (upper panel, 2 
alleles), the mother (middle panel, 2 al-
leles), and the patient (lower panel). Note 
the presence of 4 alleles in the latter, of 
which the red-circled alleles are the minor 
in distribution, representing between 10–
20% of the total. 
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tensity exceeds normal values. The minor alleles repre-
sent between 10–20% of the total. These findings again 
support a tetragametic chimeric constitution. In parallel, 
a genome-wide SNP array was performed, showing an 
aberrant profile compared to a normal control ( Fig. 5 ). 
The pattern indicated that besides a major population, 
composed of 2 alleles (either homozygous or heterozy-
gous), a minor population is identified. In addition, the 
results of the targeted Ion Torrent sequencing approach 
were overall in line with the array observations. It showed 
that a relative large group of low frequency alleles (81 
SNPs on 48 amplicons, average LAF of 6.6%) is present in 
blood-derived DNA, as well as a group of 15 genomic po-
sitions (9 amplicons on 7 chromosomes) with an average 
LAF of 12.7% ( Fig. 6 ). For several chromosomes, regions 
with either frequency are present. Of interest is the fact 
that none of these low frequency domains map to the var-
ious regions showing an additional pattern of complexity 
in the SNP array data with (partial) loss of one of the het-
erozygous SNPs of the minor population ( Fig. 6 , regions 
marked with an asterisk). Overall, these data are again in 
line with the presence of 4 alleles, with a major as well as 
a minor cell population, the latter being estimated to be 
around 12% of the total.
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 Fig. 5. HC850 SNP array analysis of a normal control 46,XX (left panel) and the 46,XX/46,XY chimeric male patient (right panel) show-
ing the multiple (3 or 4) alleles at loci throughout the genome. Arrow heads indicate the broad bands of the B-allele frequencies. The 
upper panels indicate the overall relative copy numbers. 
 Fig. 6. Representation of the combined 
molecular data of the tetragametic patient. 
Array SNP B-allele frequencies (AF) are 
plotted in grey dots (similar to the informa-
tion indicated in Figure 5 , right panel). The 
filled arrow heads indicate the major ho-
mozygous SNPs. The open arrow heads in-
dicate minor heterozygous frequency 
groups. The asterisks mark regions lacking 
the minor frequency groups on multiple 
chromosomes. The LAF data (right axis) at 
heterozygous positions are obtained from 
targeted sequencing of 3 normal peripheral 
blood DNA samples (white circles) and the 
patient DNA blood derived sample (red 
circles). The status of the various polymor-
phic markers tested is shown with dia-
monds at their genomic position. +M, ad-
ditional maternal allele, +P, additional pa-
ternal allele, +PM, additional paternal and 
maternal alleles; NI, noninformative. 
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 Discussion 
 The male patient described here had no sign of atyp-
ical genitalia and had scrotal gonads, but he was diag-
nosed with bilateral OT-DSD. A profound genetic and 
blood typing investigation revealed a defined genetic 
constitution, tetragametic chimerism, likely explaining 
the existence of bilateral ovotestes. The first gonad was 
surgically removed because of suspicion of testicular 
cancer due to painless enlargement. The pathological di-
agnosis of the ovotestis led to the referral to the DSD 
expert team. Of special clinical interest is that the pres-
ence of gynecomastia, persisting after puberty, was the 
only physical indication of an underlying DSD, as re-
ported before [van Niekerk, 1976]. Another study also 
described gynecomastia in an XX/XY individual with-
out atypical genitalia [Alonso et al., 2007]. The subse-
quent observed formation of gonadal cysts leading to 
enlargement of the remaining scrotal gonad after com-
plete unilateral gonadectomy has also been previously 
reported in a 13 years-old patient, also showing (recur-
rent) gynecomastia [Cook and Gashti, 1979]. Moreover, 
the presence of lighter and darker skin pigmented patch-
es in a male with ambiguous genitalia following the 
Blaschko’s lines, a XX/XY chromosomal pattern, and 
OT-DSD has been reported before as well [Ramsay et al., 
2009]. These observations match the specific combina-
tion of characteristics identified in the patient described 
here, i.e., gynecomastia, (recurrent) gonadal cysts, and 
the Blaschko’s lines. Besides these similarities to report-
ed cases, there are a number of additional remarkable as 
well as clinically and scientifically significant observa-
tions which will be discussed hereafter.
 The results of the endocrine investigations at the time 
of the initial evaluation by the DSD team (i.e., after the 
unilateral gonadectomy) were unexpected for an as-
sumed normal male. Both FSH and LH levels were ele-
vated. The high–normal testosterone level suggested 
that this could not be completely attributed to gonadal 
failure. The peak of LH, associated with an LH/FSH ratio 
of 1.8, was suggestive of a female-type LH peak related 
to positive feedback to the pituitary from elevated estra-
diol concentrations produced by an ovarian follicle. The 
generated LH peak may theoretically result in ovulation, 
which could explain the recurrent gonadal pain the pa-
tient experienced. Indeed, ovulation-suggestive features 
have been reported in scrotal ovotestes in a male adoles-
cent [Kropp et al., 1995]. In fact, it has been reported 
that ovulation occurs in half of all ovotestes [van Niekerk, 
1976]. The elevated prolactin levels are likely secondary 
to hyperestrogenism, as chronically elevated levels of es-
tradiol are known to stimulate prolactin secretion [Grat-
tan and Kokay, 2008]. Elevated prolactin levels have pre-
viously been observed in males with high estradiol lev-
els, for example due to a feminizing adrenal tumor 
[Subbiah et al., 2011]. Hyperprolactinemia has also been 
reported in up to 4% of transgender women (female-
identifying individuals assigned male at birth) treated 
with estrogens [Wierckx et al., 2014].
 Clinical treatment of the complaints related to recur-
rent symptomatic ovotestes, as present in the patient de-
scribed, may consist of partial gonadectomy. This re-
quires complete removal of ovarian tissue whilst saving 
as much testicular tissue as possible. This may allow re-
tention of hormonal activity and might be sufficient for 
future fertility as well. The risk for germ cell malignancy 
in OT-DSD is overall low, as reported before, for which 
the identification of the precursor lesion, either GCNIS 
or gonadoblastoma, both characterized by a positive 
staining for OCT3/4 (POU5F1), is informative [van der 
Zwan et al., 2015; Hersmus et al., 2017; Wolffenbuttel et 
al., 2017]. OCT3/4 staining was negative in the testicular 
areas of our patient, in line with a low risk. As demon-
strated here and previously reported [Kropp et al., 1995], 
one may not succeed in removing all ovarian tissue dur-
ing partial gonadectomy, because of the approach to re-
tain testicular tissue as much as possible. The results de-
scribed illustrate that the ovarian activity and associated 
complaints of painful gonadal swelling can be success-
fully suppressed by hormonal treatment, i.e., testoster-
one application, in spite of a normal endogenous testos-
terone level. This is a relevant alternative intervention 
compared to surgery to be discussed with the patients 
involved. Theoretically, an aromatase inhibitor can ef-
fectively reduce estradiol levels as well but may induce 
polycystic ovarian tissue that through increase in size 
may compromise adjacent testicular tissue and there-
fore was not considered a suitable option. In conclusion, 
testosterone supplementation was successful in the pa-
tient to resolve his gonadal pain, although LH and estra-
diol levels were not fully suppressed. Addition of a 
GnRH analogue would more effectively suppress go-
nadotropins but was not applied because the patient ex-
perienced no complaints anymore.
 Multiple studies have been reported related to a 
46,XX/46,XY karyotype in humans, although not all in-
vestigated whether it concerned an isolated sex chromo-
somal disorder or chimerism. Some older reports refer 
to true hermaphroditism, although without histological 
characterization of the gonad(s), so that the diagnosis 
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ovotestes cannot be made with certainty. Theoretically, 
karyotyping in multiple tissues, blood typing, and SNPs 
can all be used to investigate the molecular constitution 
of XX/XY patients. The karyotyping in the patient de-
scribed was performed on cultured peripheral blood 
lymphocytes as well as buccal smears. A difference in 
distribution was found, with a predominance of the 
46,XX cell line in the first and of the 46,XY cell line in 
the latter. This can be related to culturing of the lympho-
cytes or due to an actual difference in distribution in the 
different tissues. Of interest is that both the blood typing 
results and the SNP profiling support the predominance 
of the 46,XX clone as found in the cultured lymphocytes. 
This also matches the findings of the X and Y distribu-
tions found in the gonadal tissue, although a predomi-
nance of the 46,XX cell line was observed in the ovarian 
and the 46,XY cell line in the testicular area. The ap-
proaches applied are informative to detect chimeras in 
case of similar sex chromosomal constitution of the var-
ious cell lines. This is important as detailed follow-up 
protocols exist for specific variants of DSD patients, 
paying attention to their precise health risks. Moreover, 
identification can have significant advantages, for ex-
ample related to the type of donor blood that is suitable 
in cases of an emergency because of the putative pres-
ence of different blood types. All of the results of the 
analyses performed in the patient described support the 
presence of chimerism and not sex chromosome mosa-
icism. In addition, multiple tests demonstrated the pres-
ence of 4 alleles, although in a different ratio. Various 
mechanisms are proposed to result in a tetragametic chi-
merism, explaining the number of different alleles 
[Strain et al., 1995, Giltay et al., 1998]. These include 
fertilization of 2 different oocytes by 2 sperm, followed 
by fusion of the 2 early stage embryo’s, resulting in a 
single tetragametic chimeric individual. Alternatively, it 
can result from the fertilization of both the oocyte and 
the polar body by 2 different sperm. Based on the spe-
cific SNP profile, identified both by the targeted as well 
as genome-wide approach and supported by the blood 
typing results, the first mechanism is the most likely be-
cause of the complexity of the ratio of the different al-
leles. In fact, it is expected that the second mechanism 
will result in a balanced ratio of all heterozygous SNPs 
throughout the genome, because redistribution of the 
informative SNPs over the chromosomal homologues 
does not occur post-meiotically. From a clinical genetics 
point of view, SNP array analysis is widely used and may 
coincidentally demonstrate more than 2 SNPs per locus 
within a single individual. Possible contamination of 
foreign DNA must be excluded in such cases, which is 
easily performed by retesting a new blood sample and/
or, as demonstrated here, by comparison to parental 
DNA.
 In addition to the diagnostic procedures and clinical 
management described, psychological counseling is 
warranted for patients, caretakers, and families. As in 
the patient described, ovotestes and/or chimerism are 
often diagnosed later in life as patients have been born 
with typical male or female external genitals. The pres-
ence of ovotestes, chimerism, or mosaicism (of the sex 
chromosomes) may evoke confusion and discussion 
about one’s gender in patients and parents. Gender mix-
up is extremely stressful as patients and parents experi-
ence a loss of identity and loss of all basic knowledge 
about themselves/their personality (their child/their 
child’s personality). While informing patients and par-
ents about the diagnostic findings, it is important that 
gender development is discussed in the same session by 
a well-informed professional. It should be made clear 
that the genetic findings or pathological evaluation does 
not mean that there is any doubt about the patient’s gen-
der (the patient’s experiences of being a male or female 
person). It should be explained that sexual and gender 
determination and differentiation are complex, multi-
factorial processes determined by genes, steroid action, 
and upbringing and that the karyotype alone is not all-
important in gender development [Callens et al., 2016; 
Hines et al., 2016].
 Summary and Conclusions 
 A tetragametic chimeric phenotypical male patient is 
described with bilateral scrotal ovotestis with ovulatory 
activity. Gynecomastia initially was the only clinical sign 
of DSD followed by a scrotal enlargement suspected to 
be cancer. The genetic diagnosis was based on blood typ-
ing as well as SNP investigations and was supported by 
hyperpigmentation following the Blaschko’s lines. The 
patient was treated by (partial) gonadal surgery, followed 
by hormonal treatment, with satisfactory results up to 
now. However, it remains challenging to treat symptoms, 
preserve gonadal hormonal function and possibly fertil-
ity, and manage the risk of malignant transformation. 
This case illustrates the power of a dedicated multidisci-
plinary team in the diagnostic procedures and clinical 
management of individual patients, striving to fulfill 
their personal needs by optimally using clinical opportu-
nities.
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